Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 59

1.

Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.

LeWitt PA, Hauser RA, Pahwa R, Isaacson SH, Fernandez HH, Lew M, Saint-Hilaire M, Pourcher E, Lopez-Manzanares L, Waters C, Rudzínska M, Sedkov A, Batycky R, Oh C; SPAN-PD Study Investigators.

Lancet Neurol. 2019 Feb;18(2):145-154. doi: 10.1016/S1474-4422(18)30405-8. Erratum in: Lancet Neurol. 2019 Mar;18(3):e2.

PMID:
30663606
2.

A Randomized Trial of Oral and Transdermal Rivastigmine for Postural Instability in Parkinson Disease Dementia.

McDonald J, Pourcher E, Nadeau A, Corbeil P.

Clin Neuropharmacol. 2018 May/Jun;41(3):87-93. doi: 10.1097/WNF.0000000000000275.

PMID:
29537978
3.

Analysis of DNAJC13 mutations in French-Canadian/French cohort of Parkinson's disease.

Ross JP, Dupre N, Dauvilliers Y, Strong S, Ambalavanan A, Spiegelman D, Dionne-Laporte A, Pourcher E, Langlois M, Boivin M, Leblond CS, Dion PA, Rouleau GA, Gan-Or Z.

Neurobiol Aging. 2016 Sep;45:212.e13-212.e17. doi: 10.1016/j.neurobiolaging.2016.04.023. Epub 2016 May 3.

4.

Adenosine 2A Receptor Antagonists for the Treatment of Motor Symptoms in Parkinson's Disease.

Pourcher E, Huot P.

Mov Disord Clin Pract. 2015 Jul 25;2(4):331-340. doi: 10.1002/mdc3.12187. eCollection 2015 Dec. Review. Erratum in: Mov Disord Clin Pract. 2016 Jun 01;3(3):320.

5.

In memoriam: Paul J. Bédard, MD PhD: January 19, 1942-December 26, 2014.

Blanchet PJ, Pourcher E.

Prog Neuropsychopharmacol Biol Psychiatry. 2015 Jul 3;60:132-3. Review. No abstract available.

PMID:
26153581
6.

In memoriam: Paul J. Bédard, MD PhD: January 19, 1942-December 26, 2014.

Blanchet PJ, Pourcher E.

Mov Disord. 2015 Mar;30(3):299-300. doi: 10.1002/mds.26186. Epub 2015 Feb 20. No abstract available.

PMID:
25702916
7.

Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial.

Poewe W, Seppi K, Fitzer-Attas CJ, Wenning GK, Gilman S, Low PA, Giladi N, Barone P, Sampaio C, Eyal E, Rascol O; Rasagiline-for-MSA investigators.

Lancet Neurol. 2015 Feb;14(2):145-52. doi: 10.1016/S1474-4422(14)70288-1. Epub 2014 Dec 8.

PMID:
25498732
8.

Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.

Smith KM, Eyal E, Weintraub D; ADAGIO Investigators.

JAMA Neurol. 2015 Jan;72(1):88-95. doi: 10.1001/jamaneurol.2014.2472.

PMID:
25420207
9.

Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa.

Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H; Droxidopa 302 Investigators.

Hypertension. 2015 Jan;65(1):101-7. doi: 10.1161/HYPERTENSIONAHA.114.04035. Epub 2014 Oct 27.

10.

Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.

Hauser RA, Olanow CW, Kieburtz KD, Pourcher E, Docu-Axelerad A, Lew M, Kozyolkin O, Neale A, Resburg C, Meya U, Kenney C, Bandak S.

Lancet Neurol. 2014 Aug;13(8):767-76. doi: 10.1016/S1474-4422(14)70148-6. Epub 2014 Jul 6.

PMID:
25008546
11.

A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.

Parkinson Study Group QE3 Investigators, Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, Griebner B, Watts A, Gao S, Pourcher E, Bond L, Kompoliti K, Agarwal P, Sia C, Jog M, Cole L, Sultana M, Kurlan R, Richard I, Deeley C, Waters CH, Figueroa A, Arkun A, Brodsky M, Ondo WG, Hunter CB, Jimenez-Shahed J, Palao A, Miyasaki JM, So J, Tetrud J, Reys L, Smith K, Singer C, Blenke A, Russell DS, Cotto C, Friedman JH, Lannon M, Zhang L, Drasby E, Kumar R, Subramanian T, Ford DS, Grimes DA, Cote D, Conway J, Siderowf AD, Evatt ML, Sommerfeld B, Lieberman AN, Okun MS, Rodriguez RL, Merritt S, Swartz CL, Martin WR, King P, Stover N, Guthrie S, Watts RL, Ahmed A, Fernandez HH, Winters A, Mari Z, Dawson TM, Dunlop B, Feigin AS, Shannon B, Nirenberg MJ, Ogg M, Ellias SA, Thomas CA, Frei K, Bodis-Wollner I, Glazman S, Mayer T, Hauser RA, Pahwa R, Langhammer A, Ranawaya R, Derwent L, Sethi KD, Farrow B, Prakash R, Litvan I, Robinson A, Sahay A, Gartner M, Hinson VK, Markind S, Pelikan M, Perlmutter JS, Hartlein J, Molho E, Evans S, Adler CH, Duffy A, Lind M, Elmer L, Davis K, Spears J, Wilson S, Leehey MA, Hermanowicz N, Niswonger S, Shill HA, Obradov S, Rajput A, Cowper M, Lessig S, Song D, Fontaine D, Zadikoff C, Williams K, Blindauer KA, Bergholte J, Propsom CS, Stacy MA, Field J, Mihaila D, Chilton M, Uc EY, Sieren J, Simon DK, Kraics L, Silver A, Boyd JT, Hamill RW, Ingvoldstad C, Young J, Thomas K, Kostyk SK, Wojcieszek J, Pfeiffer RF, Panisset M, Beland M, Reich SG, Cines M, Zappala N, Rivest J, Zweig R, Lumina LP, Hilliard CL, Grill S, Kellermann M, Tuite P, Rolandelli S, Kang UJ, Young J, Rao J, Cook MM, Severt L, Boyar K.

JAMA Neurol. 2014 May;71(5):543-52. doi: 10.1001/jamaneurol.2014.131.

PMID:
24664227
12.

Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study.

Emre M, Poewe W, De Deyn PP, Barone P, Kulisevsky J, Pourcher E, van Laar T, Storch A, Micheli F, Burn D, Durif F, Pahwa R, Callegari F, Tenenbaum N, Strohmaier C.

Clin Neuropharmacol. 2014 Jan-Feb;37(1):9-16. doi: 10.1097/WNF.0000000000000010.

PMID:
24434526
13.

Dopaminergic innervation of the human subventricular zone: a comparison between Huntington's chorea and Parkinson's disease.

Parent M, Bédard C, Pourcher E.

Am J Neurodegener Dis. 2013 Sep 18;2(3):221-7. eCollection 2013.

14.

Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease.

Pahwa R, Lyons KE, Hauser RA, Fahn S, Jankovic J, Pourcher E, Hsu A, O'Connell M, Kell S, Gupta S; APEX-PD Investigators.

Parkinsonism Relat Disord. 2014 Feb;20(2):142-8. doi: 10.1016/j.parkreldis.2013.08.017. Epub 2013 Sep 5.

15.

Effects of 24 wk of treadmill training on gait performance in Parkinson's disease.

Nadeau A, Pourcher E, Corbeil P.

Med Sci Sports Exerc. 2014 Apr;46(4):645-55. doi: 10.1249/MSS.0000000000000144.

PMID:
24002341
16.

Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease.

Factor SA, Wolski K, Togasaki DM, Huyck S, Cantillon M, Ho TW, Hauser RA, Pourcher E.

Mov Disord. 2013 Jun;28(6):817-20. doi: 10.1002/mds.25395. Epub 2013 Apr 15.

PMID:
23589371
17.

Investigation of C9orf72 repeat expansions in Parkinson's disease.

Daoud H, Noreau A, Rochefort D, Paquin-Lanthier G, Gauthier MT, Provencher P, Pourcher E, Dupré N, Chouinard S, Jodoin N, Soland V, Fon EA, Dion PA, Rouleau GA.

Neurobiol Aging. 2013 Jun;34(6):1710.e7-9. doi: 10.1016/j.neurobiolaging.2012.11.025. Epub 2012 Dec 27.

PMID:
23273600
18.

Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study.

Dubois B, Tolosa E, Katzenschlager R, Emre M, Lees AJ, Schumann G, Pourcher E, Gray J, Thomas G, Swartz J, Hsu T, Moline ML.

Mov Disord. 2012 Sep 1;27(10):1230-8. doi: 10.1002/mds.25098. Epub 2012 Aug 22.

PMID:
22915447
19.

Influence of risperidone on balance control in young healthy individuals.

Corbeil P, Rodrigue J, Simoneau M, Cohen H, Pourcher E.

Psychopharmacology (Berl). 2012 Jul;222(1):59-69. doi: 10.1007/s00213-011-2623-7. Epub 2012 Jan 11.

PMID:
22234381
20.

Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study.

Pourcher E, Fernandez HH, Stacy M, Mori A, Ballerini R, Chaikin P.

Parkinsonism Relat Disord. 2012 Feb;18(2):178-84. doi: 10.1016/j.parkreldis.2011.09.023. Epub 2011 Oct 13.

PMID:
22000279

Supplemental Content

Loading ...
Support Center